Key additions and promotions to team in commercial, development and
regulatory roles
CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Sage Therapeutics (NASDAQ:SAGE), a clinical-stage biopharmaceutical
company developing novel medicines to treat life-altering central
nervous system (CNS) disorders, today announced the appointment of
Michael Cloonan as Chief Business Officer. Additional executive
appointments include Christopher Silber, M.D., as Senior Vice President,
Clinical Development, Paul Hodgkins, Ph.D., as Vice President, Health
Economics and Outcomes Research and Value Demonstration and Frank
Sanders as Vice President, Sales & Marketing. In addition, Amy
Schacterle, Ph.D., has been promoted to Senior Vice President,
Regulatory Affairs and Quality Assurance.
"I am pleased to welcome Michael Cloonan, a highly-respected and very
accomplished biopharmaceutical executive, to our team. In this new
leadership role, Mike will be responsible for planning and executing an
integrated global commercial strategy," said Jeff Jonas, M.D., Chief
Executive Officer of Sage Therapeutics. "We are excited to continue our
buildout of critical leadership roles across the organization as we
progress our broadening clinical pipeline across multiple CNS disorders,
and plan for potential product commercialization next year. Mike, Chris,
Paul and Frank add new capabilities and expertise to our team as we
continue to evolve into a leading CNS company."
Michael Cloonan will lead Sage's Commercial, Portfolio and Program
Management, Medical Affairs, and Corporate Development departments. Mr.
Cloonan comes to Sage from Biogen, where he worked for 14 years. At
Biogen, Mr. Cloonan most recently served as Senior Vice President, US
Commercial, where he led a US affiliate with direct general manager
responsibility for Sales, Marketing, Market Access, Patient Services and
Commercial Operations. Previously, he held roles of increasing
responsibility at Biogen, including Senior Vice President, Global
Commercial Strategy; Vice President, Managing Director, Australia/New
Zealand affiliate; and Vice President, Business Planning. Prior to
Biogen, Mr. Cloonan worked at Bain & Company as a consultant
specializing in healthcare. Mr. Cloonan received his M.B.A. from Darden
Graduate School of Business Administration, University of Virginia and a
B.A. from College of the Holy Cross.
Chris Silber, M.D., is an experienced drug development leader with over
25 years in executive roles in the pharmaceutical industry. Dr. Silber
will lead the Medical Science, Clinical Operations and Data Science
departments at Sage and will play a key role in clinical trial design
and clinical program planning and execution. Prior to Sage, Dr. Silber
served most recently as Chief Medical Officer for Agilis Biotherapeutics
having previously held various clinical leadership roles at H. Lundbeck
A/S for seven years, including Vice President, US Clinical Development
Center and Vice President, US Clinical Research and Medical Affairs.
Before Lundbeck, Dr. Silber held clinical research and drug development
management roles at Takeda, Hospira, and Abbott Laboratories. Dr. Silber
holds an M.D. from S.U.N.Y. at Buffalo School of Medicine and a B.A. in
Psychology from Tufts University.
Paul Hodgkins, Ph.D., joins Sage from Vertex, where he served as Vice
President, Global Health Economics & Outcomes Research since 2013. Prior
to Vertex, Dr. Hodgkins held roles at Shire Pharmaceuticals including
Senior Director, Global Health Economics Outcomes Research and Senior
Global Medical Affairs Director. Dr. Hodgkins holds a BSc in
Biochemistry, Pharmacology, and Statistics from the University of
Wolverhampton, a Ph.D. in Neuroscience from Aston University, and an MSc
in Health Economics and Management from the University of Sheffield.
Frank Sanders joins Sage with over 20 years of experience in the
biopharmaceutical industry. Mr. Sanders will have responsibility for the
development of marketing strategies and market growth plans, along with
account management execution for the US market. Most recently, Mr.
Sanders served as Vice President, Strategic Account Management at
Janssen Pharmaceutical Companies of Johnson & Johnson. Previously, Mr.
Sanders held a wide range of senior leadership roles for
GlaxoSmithKline, including Vice President, Marketing, Customer Strategy
and Vice President, Field Sales. Mr. Sanders holds a B.A. in Business
Administration from Wittenberg University.
Amy Schacterle, Ph.D., has been at Sage since 2014. She has led Sage's
successful interactions with global regulatory authorities and has
overseen the filing of several Investigational New Drug (IND)
applications. In addition, Dr. Schacterle has led Sage's efforts in
accelerating its development programs through regulatory initiatives,
such as obtaining Breakthrough Therapy and PRIority MEdicines (PRIME)
designations for Sage's Phase 3 program for postpartum depression.
About Sage Therapeutics
Sage Therapeutics is a clinical-stage biopharmaceutical company
committed to developing novel medicines to transform the lives of
patients with life-altering central nervous system (CNS) disorders. Sage
has a portfolio of novel product candidates targeting critical CNS
receptor systems, GABA and NMDA. Sage's lead program, brexanolone
(SAGE-547), is in Phase 3 clinical development for super-refractory
status epilepticus, a rare and severe seizure disorder, and for
postpartum depression. Sage is developing its next generation
modulators, including SAGE-217 and SAGE-718, in various CNS disorders.
For more information, please visit www.sagerx.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170424005510/en/
Investors:
Sage Therapeutics
Paul Cox, 617-299-8377
paul.cox@sagerx.com
or
Media:
Suda
Communications LLC
Maureen L. Suda, 585-387-9248
maureen.suda@sagerx.com
Source: Sage Therapeutics
News Provided by Acquire Media